<DOC>
	<DOC>NCT01804361</DOC>
	<brief_summary>The purpose of this study is to determine efficacy and safety of Haporine-S eye drop for the patients with moderate to severe dry eye disease in a multicenter phase III clinical trial.</brief_summary>
	<brief_title>Efficacy and Safety Study of Haporine-S for Treatment of Moderate to Severe Dry Eye Syndromes</brief_title>
	<detailed_description>This study is to compare the efficacy and the safety of topical Haposine-S and RestasisÂ® eye drop 0.05% for the patients with moderate to severe dry eye disease in a multicenter, investigator(assessor) blind, parallel design, non-inferiority phase III trial. Primary outcome is the change of corneal staining score(Oxford scheme) at 12 weeks from baseline.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Male or female, age 20 or over Patients with moderate to severe dry eye(DEWS Level II or over) Be informed of the nature of the study and will give written informed consent Being treated with steroidal eye drop or nonsteroidal antiinflammatory eye drop for dry eye Being treated with systemic steroid or immunosuppressive History of eyeball surgical operation within 6 months Wearing contact lenses during participation of the study Pregnancy or breastfeeding Use of cyclosporine eye drop within 2 weeks Intraocular pressure(IOP)&gt; 25 mmHg History of punctal occlusion within 1 month or during participation of the study Hypersensitivity to the investigational products or be suspicious to them Patients whom the investigator considers inappropriate to participate in the study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Dry Eye Syndromes</keyword>
</DOC>